**H. influenzae** serotypes and NTHi (I; https://www.cdc.gov/meningitis/lab-manual/full-manual.pdf; online Technical Appendix Table). In Oman, it is mandatory to report cases of Hib meningitis within 24 hours of laboratory diagnosis, and those caused by other serotypes and NTHi within 1 week, to the Department of Communicable Disease Surveillance and Control, Ministry of Health. Evidence of capsule-deficient variants of Hia that cannot be differentiated from NTHi by conventional methods (7) and recurrent invasive diseases (9,10) and outbreaks caused by Hia (9; online Technical Appendix Table) emphasize the necessity for continued surveillance, strong laboratory support, and local epidemiologic studies on non-b *H. influenzae* disease.

Hia meningitis has been reported mainly in the indigenous peoples of Canada, Alaska (USA), and Australia; in the Navajo and White Mountain Apache tribes in the southwestern United States; and in Utah (USA), Brazil, the Gambia, East Africa, and Papua New Guinea. Sporadic cases have been reported in the rest of the world (I, 10; online Technical Appendix Table). The reasons behind the high rates of invasive Hia disease among indigenous children remain unclear (I). In Canada, where invasive non-b *H. influenzae* disease has been included in the list of nationally reportable diseases (http://diseases.canada.ca/notifiable/diseases-list) since 2007, a public health–driven initiative has been established to provide a better characterization of the epidemiology of invasive Hia disease and develop a candidate vaccine against Hia (online Technical Appendix Table).

Dr. Sawardekar is a senior consultant in the Department of Pediatrics at Nizwa Hospital, Nizwa, Oman. His primary research interests are pediatric infectious diseases and congenital malformations.

**References**


**Address for correspondence:** Kiran P. Sawardekar, Department of Pediatrics, Nizwa Hospital, Nizwa, Postal Code 611, Sultanate of Oman; email: sawarkiran@gmail.com

### Importation of Zika Virus from Vietnam to Japan, November 2016

**Takehiro Hashimoto, Satoshi Kutsuna, Shigeru Tajima, Eri Nakayama, Takahiro Maeki, Satoshi Taniguchi, Chang-Kweng Lim, Yuichi Katanami, Nozomi Takeshita, Kayoko Hayakawa, Yasuuyuki Kato, Norio Ohmagari**

Author affiliations: National Center for Global Health and Medicine, Tokyo, Japan (T. Hashimoto, S. Kutsuna, Y. Katanami, N. Takeshita, K. Hayakawa, Y. Kato, N. Ohmagari); National Institute of Infectious Diseases, Tokyo (S. Tajima, E. Nakayama, T. Maeki, S. Taniguchi, C.-K. Lim)

DOI: https://dx.doi.org/10.3201/eid2307.170519

We report a case of Zika virus infection that was imported to Japan by a traveler returning from Vietnam. We detected
Zika virus RNA in the patient’s saliva, urine, and whole blood. In the Zika virus strain isolated from the urine, we found clearly smaller plaques than in previous strains.

Zika virus has been documented in Southeast Asia since the 1940s; however, the prevalence and geographic extent of Zika virus disease in Asia remain unclear (1). In Vietnam, 219 cases of Zika virus infection were reported in 2016 and 13 new cases in 2017 (2). We report a case of Zika virus infection imported from Vietnam to Japan, diagnosed after PCR amplification of Zika virus RNA in the patient’s saliva, urine, and whole blood.

A 40-year-old man came to the National Center for Global Health and Medicine in Tokyo, Japan, in the middle of November 2016 with fever and a rash. In early November 2016, he had traveled to Ho Chi Minh City, Vietnam, where he stayed for 10 days. During his return to Japan, he developed fever and a diffuse rash on his face, trunk, arms, and legs. He went to the hospital on the day after his return and reported having been bitten by mosquitoes in Ho Chi Minh City. Upon arrival at the hospital, he had no fever (temperature 36.8°C); physical examination revealed conjunctivitis and a maculopapular rash on his face, trunk, and extremities. Results of laboratory tests showed leukopenia (2,250 cells/µL; reference 3,500–8,500 cells/…
µL) and a platelet count within reference range. We performed a rapid dengue test (Dengue Duo NS-1 Ag + Ab combo; SD Bioline, Standard Diagnostics Inc., Gyeonggi-do, South Korea); results were negative for nonstructural protein 1, IgM, and IgG. We performed real-time reverse transcription PCR (RT-PCR) amplification using Zika virus primers and probes with urine, saliva, whole blood, serum (obtained 4 days after symptom onset), and semen samples (obtained 6 days after symptom onset). We detected Zika virus RNA in the urine (cycle threshold [Ct] 32.0), saliva (Ct 39.1), and whole blood (Ct 38.1) samples. However, we did not detect Zika virus RNA in the serum or semen samples. We diagnosed Zika virus infection in this patient; his symptoms resolved without treatment within 7 days after he initially sought care.

We successfully isolated the infectious Zika virus from the urine specimen. We amplified the nearly complete genome (10,696 bases; GenBank accession no. LC219720) of the Zika virus from the isolate using RT-PCR and subsequently sequenced it. BLAST analysis (https://blast.ncbi.nlm.nih.gov/Blast.cgi) showed that the isolate was an Asian lineage virus (3), sharing 99.3% sequence identity with the Zika virus strain isolated in French Polynesia in 2013 (H/PF/2013; GenBank accession no. KJ776791), 98.9% identity with the strain isolated in Fiji in 2016 (ZIKV/Hu/S36/Chiba/2016; GenBank accession no. LC191864), 99.0% identity with the strain isolated in Puerto Rico in 2015 (PRV-ABC59; GenBank accession no. KU501215), and 88.5% identity with the strain isolated in Uganda in 1947 (MR766-NIID; GenBank accession no. LC002520). The phylogenetic tree that we constructed using the complete coding region of the Zika virus genome suggested that the sequence belonged to the Southeast Asian clade of the Asian lineage (Figure). The plaque size of the isolated strain in Vero cells was obviously smaller than that of the Asian strain ZIKV/Hu/S36/Chiba/2016 (Pacific clade). We also confirmed that the plaque sizes of the PRVABC59 (American clade) and MR766-NIID (African clade) strains resemble that of ZIKV/Hu/Chiba/S36/2016 (data not shown), suggesting that the Southeast Asian clade Zika virus strains might have a lower cytotoxicity and replicative ability than the American clade and African lineage.

In conclusion, the replicative ability of Zika virus might differ by region and thus influences endemic potential. Further studies are necessary to validate these findings.

This work was supported by a grant from the Japan National Center for Global Health and Medicine (27-6001).

Dr. Hashimoto is a medical doctor at the National Center for Global Health and Medicine, Disease Control and Prevention Center, in Tokyo, Japan. His main research interest is tropical infectious diseases.

References

RESEARCH LETTERS
Human African trypanosomiasis has not been reported in Nigeria since 2012. Nevertheless, limitations of current surveillance programs mean that undetected infections may persist. We report a recent case of stage 2 trypanosomiasis caused by Trypanosoma brucei gambiense acquired in Nigeria and imported into the United Kingdom.

In January 2016, the patient experienced leg tremors and lethargy. These symptoms persisted until arrival in the United Kingdom in May 2016. Over the next 2 months, increasing malaise and unsteadiness in walking developed. In August 2016, the patient was admitted to a regional hospital with confusion and drowsiness. She was febrile at admission but had no lymphadenopathy; neurologic examination revealed no neck stiffness or photophobia, but did show poor coordination with slow cognitive processes.

Laboratory investigations revealed microcytic anemia with a C-reactive protein level of 13 mg/L (reference value <5 mg/L) and a total serum IgM of 13.7 g/L (reference range 0.5–2.0 g/L). A blood film was negative for malaria. Confirmatory assays after positive screening assay results for HIV and syphilis antibodies showed the original results to be false positive.

Cerebrospinal fluid (CSF) examination revealed 331 leukocytes/mm³, 99% lymphocytes; CSF protein level 0.82 g/L (reference range 0.23–0.38 g/L); and glucose level was >50% plasma glucose. Results of CSF PCR for herpesviruses, enterovirus, and JC virus were negative. Results of GeneXpert (Cepheid, Buckinghamshire, UK) tests of CSF and mycobacterial culture were negative. Magnetic resonance imaging of the brain showed, on T2 weighted and flair images, bilateral diffuse hyperintensities within white matter located in the periventricular regions, basal ganglia, cerebellum, and brainstem.

Treatment with ceftriaxone, acyclovir, antituberculous treatment and prednisolone was stopped at 14 days because of a lack of clinical improvement and drug-induced transaminis.

The patient’s lethargy, intermittent confusion, and periods of somnolence became more severe. Examination in August 2016 revealed intention tremor in all limbs and myoclonic jerks. Her case was discussed with the Imported Fever Service at Public Health England. A serum sample was sent to the Hospital of Tropical Diseases in London, UK for T. brucei gambiense indirect fluorescent antibody testing (IFAT), which showed a positive result (titer 1:400). The patient was transferred to this hospital.

Repeat CSF examination revealed a protein level of 1.14 g/L, CSF glucose level of 2.3 mmol/L (serum 5.5 mmol/L), and 1,140 leukocytes/mm³ (90% mononuclear). No trypanosomes were seen in theuffy coat of peripheral blood or CSF. CSF total IgM of 1.98 mg/L (reference range 0–0.9 mg/L) and IgG of 306 mg/L (reference range 10–40 mg/L) were markedly raised (2).

T. brucei gambiense IFAT results for CSF (titer 1:4) and blood (titer 1:400) were positive. DNA extracted from CSF was positive for trypanosomes of the subgenus Trypanozoon by PCR (3) and confirmed as T. brucei gambiense group I by diagnostic PCR with TgsGP primers (4). The result of immune trypanolysis was negative.